Sensei biotherapeutics announces first patient dosed in phase 1/2 clinical trial of sns-101, a conditionally active vista-blocking antibody, for the treatment of advanced solid tumors

- topline phase 1 monotherapy and initial combination data expected in 2024 - boston, june 01, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the first patient has been dosed in its phase 1/2 clinical trial evaluating sns-101 for the treatment of advanced solid tumors. sns-101 is a conditionally active, human monoclonal igg1 antibody, designed to selectively block the immune checkpoint vista in the tumor microenvironment, which acts as a suppressor of t cells by binding the receptor psgl-1.
SNSE Ratings Summary
SNSE Quant Ranking